Table 3.

Agreement between XTT- and NCCLS-derived MICs

Species (no. of isolates) and antifungal agent % Agreement within 1 well (no. with agree- ment/no. tested)a
C. albicans (29)
Amphotericin B97 (28/29)
Fluconazole94 (27/29)
Itraconazole94 (27/29)
Ketoconazole97 (28/29)
Flucytosine100 (29/29)
C. glabrata (12)
Amphotericin B100 (12/12)
Fluconazole100 (12/12)
Itraconazole100 (12/12)
Ketoconazole100 (12/12)
Flucytosine100 (12/12)
C. tropicalis (17)
Amphotericin B100 (17/17)
Fluconazole100 (17/17)
Itraconazole100 (17/17)
Ketoconazole100 (17/17)
Flucytosine100 (17/17)
C. guilliermondii(6)
Amphotericin B100 (6/6)
Fluconazole100 (6/6)
Itraconazole100 (6/6)
Ketoconazole100 (6/6)
Flucytosine100 (6/6)
C. parapsilosis (18)
Amphotericin B89 (16/18)
Fluconazole89 (16/18)
Itraconazole72 (13/18)
Ketoconazole78 (14/18)
Flucytosine83 (15/18)
C. lusitaniae (11)
Amphotericin B91 (10/11)
Fluconazole91 (10/11)
Itraconazole45 (5/11)
Ketoconazole64 (7/11)
Flucytosine91 (10/11)
C. krusei (5)
Amphotericin B80 (4/5)
Fluconazole80 (4/5)
Itraconazole100 (5/5)
Ketoconazole100 (5/5)
Flucytosine100 (5/5)
C. neoformans (20)
Amphotericin B100 (20/20)
Fluconazole100 (20/20)
Itraconazole100 (20/20)
Ketoconazole100 (20/20)
Flucytosine100 (20/20)
• a Agreement is expressed as the percentage of isolates for which XTT MICs were within 1 dilution of the NCCLS MIC. Note that there was 100% agreement for all isolates and agents of XTT MICs within 2 dilutions of the NCCLS MIC.